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1. Introduction 
Type 1 diabetes is (T1D) is an autoimmune disorder characterized by the T-cell-mediated 
destruction of the insulin-secreting  cells of the pancreatic islet of Langerhans.  
T1D is heterogeneous in terms of age at diabetes development with as many adults 
developing the disorder as children(Barnett et al 1981). Genetic susceptibility is dependent 
on the degree of genetic identity with the proband, and the risk of diabetes in families has a 
non-linear correlation with the number of alleles shared with the proband. The highest risk 
is naturally observed in monozygotic twins (100% sharing) followed by first, second, and 
third degree relatives (50%, 25%, 12.5% sharing, respectively) (Millward et al 1986).  
About 18 regions of the genome have been linked with influencing T1D risk. These regions, 
each of may contain several genes. Over 40 genes and loci have been associated with T1D 
(Barett et al 2009) have been labeled IDDM1 to IDDM18. 
The most well studied is IDDM1, which contains the HLA genes that encode immune 
response proteins. Variations in HLA genes are an important genetic risk factor, but they 
alone do not account for the disease and other genes are involved. There is increasing 
evidence other MHC linked gene or loci with a potential impact on the risk to T1D exist 
(Renando et al 2001). 
There are three other non-MHC genes which have been identified thus far. One of these 
non-MHC genes is the insulin gene, and the other non-MHC gene maps close to CTLA4, 
which has a regulatory role in the immune response and the third confirmed non-MHC 
gene is PTPN22 that is involved in modulating T-cell activation. 
2. Global distribution of T1D  
T1D is reaching epidemic proportions throughout the world. The incidence of T1D is 
rapidly increasing in specific regions T1D affects incidence is highly variable among 
different populations. The overall ratio of incidence of T1D varies from 0.1/100 000 per year 
in China to more than 36/100 000 per year in Sardinia and in Finland. This drastic variation, 
a more than 350-fold,  among populations is analyzed (Kavvoura &Ionnidis 2005).The polar 
equatorial gradient (i.e., north-south gradient) described for disease incidence is not as 
strong as previously thought (e.g. for example Sardinia with extremely high incidence). 
Most populations with very high incidence rates are Europid. Although it is well established 
that the incidents rate of T1D is as low as 0.1/100 000 amongst Asians (Kavvoura & Ionnidis 
2005) high incidence rates have also been noted in Kuwait(Shaltout et al 2002), Oman 
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(Abdullah 2005), Bahrain (Jahromi unpublished) and Puerto Rico (Karvonen et al 2000). In 
fact, a relatively high gradient risk has been reported among some non-Europid ethnicities 
(i.e., admixed partly African [1/100 000 per year in Mauritius versus 15/100 000 per year in 
Chicago] and Arab [5/100 000 per year in Sudan vs. 21/100 000 per year in Kuwait] 
(Shaltout et al 2002).  
2.1 Pathogenesis 
T1D develops slowly and progressive abnormalities in pancreatic ǃ cell function herald 
what appears to be a sudden development of hyperglycemia.  Rising HbA1c in the normal 
range(Stene et al 2006), impaired fasting or glucose tolerance, as well as loss of first phase 
insulin secretion usually precede overt T1D.  The exact pancreatic ǃ cell mass remaining at 
diagnosis is poorly defined and there is almost no studies of insulitis prior to onset of 
T1D(Gianani et al 2006).  For patients with long-term T1D there is evidence of some ǃ cell 
function remaining (C-peptide secretion) though ǃ cell mass is usually decreased to less 
than 1% of normal(Meier et al 2005).  At present methods to image/quantitate ǃ cell mass 
and insulitis are only beginning to be developed.  However, animal studies have provided 
the first methods to image islet mass utilizing a labeled amine (dihydrotetrabenazine) 
(Souza et al 2006) A number of techniques are being evaluated to image insulitis. 
An increasing body of evidence indicates that the development of T1D is determined by a 
balance between pathogenic and regulatory T lymphocytes (Jahromi et al 2010).  A 
fundamental question is whether there is a primary autoantigen for initial T cell 
autoreactivity with subsequent recognition of multiple islet antigens.  A number of 
investigators have addressed in the NOD mouse (spontaneously develops T1D) the 
importance of immune reactivity to insulin with the dramatic finding that eliminating 
immune responses to insulin blocks development of diabetes and insulitis, and importantly 
immune responses to downstream autoantigens such as the islet specific molecule 
IGRP(Krishnamurthy et al 2006).  Knocking out both insulin genes (mice in contrast to man 
have two insulin genes) with introduction of a mutated insulin with alanine rather than 
tyrosine at position 16 of the insulin B chain prevents development of diabetes(Nakayama et 
al 2005).  Recognition of this B-chain peptide of insulin by T lymphocytes depends upon a 
“non-stringent” T cell receptor with conservation of only the alpha chain sequence (Valpha 
and Jalpha) and not the N-region of the alpha chain, or the ǃ chain( Homann & Eisenbarth 
2006).   
Interestingly, a study of pancreatic lymph node from two patients with T1D found a 
conserved T cell receptor, with T cells reacting with insulin A chain peptide amino acids 1-
15. 
There are large scale studies such as T1DGC (Barrett et al 2009)  (USA), Teddy 
(International), (Nakayama et al 2005) ,  DAISY (Liu et al 2005), DIPP BabyDiab( Homann & 
Eisenbarth 2006) and where tens of thousands of infants have been HLA typed and followed 
from birth for the development of islet autoantibodies and then progression to diabetes. 
Although T1D rate is increasing in Arabian countries recently, however, centers with 
diabetes interest have been found in Kuwait, UAE, Qatar, Bahrain as well as Saudi Arabia 
that would help in case of international contribution in determining the T1D pathogenesis.   
Especially since there are likely changing environmental factors contributing to the world-
wide increase in the incidence of T1D and the above studies, in addition to providing crucial 
information for prediction are searching for such factors.   
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2.2 Genetic of T1D    
2.2.1 “Monogenic” inheritance 
The immune dysregulation, Polyendocrinopthay, Enteropathy, X-linked (IPEX) syndrome is 
caused by a mutation of the foxP3 gene, a transcription factor that controls the development 
of regulatory T cells is a cause of neonatal diabetes( Jahromi & Eisenbarth 2007). 
As reflected in the name, children with disorder suffer from overwhelming autoimmunity 
and usually die as infants.  Of note bone marrow transplantation can reverse disease. IPEX 
syndrome is rare, as is neonatal diabetes.  In the differential diagnosis of neonatal diabetes it 
must be recognized that half of children developing permanent neonatal diabetes have a 
mutation of the Kir6.2 molecule of the sulfonylurea receptor.  These children with their non-
autoimmune form of diabetes can be treated with oral sulfonylurea therapy. 
Though more common than IPEX syndrome, the APS-1 syndrome (Autoimmune 
Polyendocrine Syndrome Type 1) is also rare.  It results from a mutation of the AIRE gene, 
another transcription factor(Jahromi & Eisenbarth 2007).  Approximately 15% of patients 
with this syndrome develop autoimmune diabetes.  The leading hypothesis as to etiology 
(e.g. Addison’s disease, mucocutaneous candidiasis, and hypoparathyroidism) is that AIRE 
controls expression of autoantigens and negative selection of autoreactive T lymphocytes 
within the thymus. A very recent dramatic discovery is the demonstration that essentially 
100% of patients with APS-1 have autoantibodies reacting with interferon alpha and other 
interferons.  Such autoantibodies are extremely rare and essentially not found in patients 
with T1D or Addison’s disease outside of the syndrome.   
Patients with T1D and their relatives are at risk for development of thyroid autoimmunity, 
celiac disease, Addison’s disease, pernicious anemia and a series of other autoimmune 
disorders(Aly et al 2006). Approximately 1/20 patients with T1D have celiac disease by 
biopsy though the majority have no symptoms(Hoffenberg et al 2004).  These asymptomatic 
individuals are usually detected with screening for transglutaminase autoantibodies.  The 
level of transglutaminase autoantibodies relates to the probability of a positive biopsy and it 
is important for clinicians to know the threshold for likely positive biopsy for the assay they 
employ(Liu et al 2005).  There remains controversy as to whether asymptomatic celiac 
disease when detected should be treated with a gluten free diet and large clinical trials are 
needed to address this question.   
2.2.2 “Polygenic inheritance” 
T1D has become one of the most intensively studied polygenic disorders. There are rare 
variants of immune mediated diabetes with single gene mutations including the APS-I 
syndrome (AIRE autoimmune regulator gene) and the IPEX syndrome (Fox P3 mutation) ( 
Jahromi & Eisenbarth 2006). Multiple genetic factors influence both susceptibility and 
resistance to the common forms of T1D( Barrett et al 2009). Although a significant 
proportion of patients with T1D lack a family history of the disease, there is significant 
familial clustering with an average prevalence of 6% in siblings compared to 0.4% in the US 
Caucasian population. Of note, there is a 3.8 % risk of T1D in Japanese siblings of patients 
with T1D compared to 0.01~0.02 % prevalence in the general Japanese population 
(Hoffenberg 2004). The sibling ratio (λs) can be calculated as the ratio of the risk to siblings 
over the disease prevalence in the general population, and thus λs = 6/0.4= 15 and 
3.8/0.01~0.02=>100 for the US and Japan respectively (Hoffenberg 2004). 
Genetic susceptibility of different genes and loci have been identified using both association 
and linkage studies. Using the candidate gene approach, association studies provided 
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evidence for the first two susceptibility loci, the HLA region and the insulin gene (INS) locus. 
These two loci only contribute a portion of the familial clustering (40-50% for HLA and 10% for 
INS), suggesting the existence of additional loci (Aly et al 2006, Jahromi & Eisenbarth 2006 & 
2007, Barrett et al 2009). The next most potent locus for T1D of man was also discovered using 
a candidate gene approach, namely the LYP (PTPN22) gene with an odds ratio of 
approximately 1.7 for a "missense" mutation that contributes to multiple different autoimmune 
disorders (. Recently, however, Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene and SUMO-4 
with weak association were described following genome analysis. For both the associations 
appear heterogeneous dependent on the population (e.g. stronger association of Sumo-4 in 
Asian populations and lack of association in multiple European populations) (Nielsen et al 
2011) , and nature of the disease (e.g. CTLA-4 associated with diabetes with thyroid 
autoimmunity) (Meier et al 2005). Undoubtedly, large extensive control case studies will reveal 
more loci, each providing a piece to the genetic puzzle of T1D, but with difficulty of 
distinguishing false positive signals with very weak associations.  
2.2.2A The Major Histocompatibility Complex (MHC) 
The major loci for susceptibility to T1D are located within the HLA (Human Leukocyte 
Antigen) region on the short arm of chromosome 6 and provide up to 40-50% of the inheritable 
T1D risk(Jahromi & Eisenbarth 2006, Barrett et al 2009, Jahromi et al 2010, Neilson et al 2011).  
2.2.2A1 The HLA classes 
Within the MHC region, they are grouped into three classes. Class I genes: (HLA - A, HLA -
B and HLA-C as major & HLA-D, HLA-E, and HLA-F as minor subclasses) (Marsh et al 
2005) encode class I MHC antigens, located on the surface of all nucleated cells (Jahromi & 
Eisenbarth 2007). The HLA complex was first linked to T1D when associations with several 
HLA class I antigens (eg HLA-B8, -B18, and -B15) were discovered by serological typing and 
affected sib-pair analysis showed evidence of linkage(Todd et al 1989, Awata et al 1990). 
Class II genes: (DQ, DR, and DP in that order of risk) were shown to be even more strongly 
associated with the disease (Todd et al 1989, Mijovic et al 1991). HLA class II antigens are 
found exclusively on B-lymphocytes, macrophages, epithelial cells of the islets of pancreatic 
Langerhans and activated T-lymphocytes. Their expression on other cells may be induced 
by cytokines such as interferon (IFN) and tumor necrosis factor (TNF)-ǂ (Jahromi et al 2000). 
With the development of typing reagents, HLA class II alleles. However, other loci within or 
near the HLA complex appear to modulate T1D risk, and add further complexity to the 
analysis of IDDM1 -encoded susceptibility. HLA Class III:  The TNF (Tumor Necrosis 
Factor) gene is a strong candidate from class III, Table 1.  
 
 
Major histocompatibility 
complex (MHC)/ Human 
leukocyte antigen (HLA) 
MHC class I HLA-A  HLA-B HLA-C  HLA-
E  HLA-F  HLA-G (Bodmer et al 1992) 
 
MHC class II 
HLA-DM (ǂ, ǃ)  HLA-DO (ǂ, ǃ)  
HLA-DP (ǂ1, ǃ1)  HLA-DQ (ǂ1, 
ǂ2, ǃ1, ǃ2, ǃ3)  HLA-DR (ǂ, ǃ1, ǃ3, 
ǃ4, ǃ5) (Marsh et al 2005) 
MHC class III  
Table 1. Different classes of Major Histocompatibility Complex 
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The great majority of Caucasian patients have the HLA-DR3(with [DQA1*0501, 
DQB1*020]DQ2) or -DR4(with [DQA1*0301,DQB1*0302]DQ8) class II alleles and 
approximately 30% to 50% of patients are DR3/DR4 heterozygotes ( Barrett et al 2009). The 
DR3/DR4 (DQ2, DQ8) genotype confers the highest diabetes risk with a synergistic mode of 
action, Table 2 (Mitchel et al 2007). However, DR4/DR9 has been reported to be a highly 
susceptible haplotype in Japanese. The absence of DR3 haplotypes in Japanese population 
may contribute to lower frequency of the disease in Japan (Fain & Eisenbarth 2002).   On the 
other hand, in Chinese population the DR3/DR9 genotype is highly susceptible (Xiao-mei et 
al 2009). In fact DQ-DR linkage disequilibrium patterns of HLA haplotypes in different 
populations may explain part of the world-wide differences in the frequency of incidence of 
T1D  (e.g.DRB1*0405-DQB1*0302 is a high risk haplotype while DRB1*0403-DQB1*0302 is 
neutral or protective). In Arab population, however, patients with T1D have almost similar 
HLA genetic susceptibility as Caucasian patients, this may confirms the increase rate of 
incidents of T1D (Shaltout et al 2002, Al Abbasi et al 2002).  
 
 Relative risk
HLA-DR3 5  
HLA allele 6 
HLA-DR3/DR4 16 
Extracted from Mitchel et al 2007 
Table 2. HLA and T1D with increased risk 
Furthermore, DRB1*1501-DQB1*0602 is protective in all populations which have been 
studied to date (shaltout et al 2002, Caillat et al 1997, Escribano-De-Diego et al 1999, 
Kawasaki et al 2004).  Analysis of rare “recombinant” haplotype suggests that DQB1*0602 
provides protection and not DRB1*1501.   
Specific allelic combination of DR/DQ loci have been shown to determine the haplotypic 
risk for T1D, protective and susceptible. Table 4 have summarized the most susceptible and 
the most protective combinations. The comparison of closely related DR-DQ haplotype pairs 
 
DRB1 DQA1 DQB1 Effect on T1D 
0405 0301 0302 S1 
0401 0301 0302 S2 
0301 0501 0201 S3 
0402 0301 0302 S4 
0404 0301 0302 S5 
0701 0201 0503 P1 
1401 0101 0503 P2 
1501 0102 0602 P3 
1104 0501 0301 P4 
1303 0501 0301 P5 
Haplotype frequency in either proband or control subjects, five most susceptible (S) and five most 
protective (P) haplotypes are indicated (Erlik et al 2008) 
Table 3. Frequency distribution of DRB1-DQB1 haplotype 
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with different T1D risks allowed identification of specific amino acid positions critical in 
determining disease susceptibility, only a single change of an amino acid would change 
degree of genetic susceptibility drastically (Erlick et al 2008).  
On the other hand, combined typing of high risk HLA alleles with analysis of HLA 
haplotype sharing can identify siblings with an extraordinary genetic risk of T1D. This 
strongly implicates major genes in addition to DR and DQ alleles. The current extensive   
MHC analysis and multiple studies of conserved haplotypes (eg. A1-B8-DR3-DQ2 common 
extended haplotype)( Alper et la 1992) conferring increased risk.  Increasing studies have 
confirmed the significant association of HLA-F region in determining the risk for T1D (Al et al 
2008, Barett et al 2009, Brorsson et al 2009). Interestingly through out our large affected family 
based controls (AFBAC) we have found that there is significant signal between patients with 
T1D and controls in HLA-F region in particular that contributes to T1D risk which seems to go 
with DRB*0401, but has an independent risk. In other words this signal may have certain link 
with the possible candidate gene susceptible to T1D other than DQ/DR (Jahromi in process).  
2.2.2B Non MHC genes 
There are about 40 non MHC genes or loci which are candidates for genetic susceptibility to 
T1D (Barrett et al 2009). The most well known are discussed in this chapter. 
2.2.2B1 Insulin gene  
Insulin is composed of two distinct polypeptide chains, chain A and chain B, which are 
linked by disulfide bonds. Many proteins that contain subunits, such as hemoglobin, are the 
products of several genes. However, insulin is the product of one gene, INS. The research 
done by Nakayama and coworkers have strongly shown that insulin is a primary 
autoantigen in the beginning stages of diabetes (Nakayama et al 2005). 
Also, supporting this evidence is the presence of insulin antibodies in the blood of 
prediabetic and diabetic patients. The insulin gene is the second well established 
susceptibility locus in T1D on chromosome 11p 15.5 (Jahromi & Eisenbarth 2006).  
The 4.1 Kb region containing the insulin gene (INS) and its flanking regions contain several 
polymorphisms in linkage disequilibrium (Stead et al 2000) that have been associated with 
diabetes risk. All the polymorphisms identified within this region lie outside coding 
sequences, confirming that diabetes susceptibility must derive from genetic influences on 
the expression of the insulin gene. Extensive studies involving polymorphisms in the 
neighboring HUMTHO1 (tyrosine hydroxylase) and IGF2 genes provided strong evidence 
that INS is the main susceptibility determinant in this region ( Vardi et al 1988,Stead et al 
2000). Shortly after its discovery (Vardi et al 1987), the insulin VNTR was found to be 
associated with T1D (Haskins & Wegman 1996). Susceptibility in the INS region, or the 
IDDM2 locus, was initially associated to a variable number of tandem repeats (VNTR) 
located ~0.5 kb upstream of (INS) (Vardi et al 1987, Haskins & Wegman 1996, Yu et al 2000). 
Homozygosity for the short class VNTR I alleles is found in ~75-85% of the patients 
compared to a frequency of 50-60% in the general population, suggesting that it predisposes 
to T1D. In contrast, homozygosity for the longer class III VNTR alleles is rarely seen in 
patients and the class III VNTR is believed to confer a dominant protective effect (Haskins & 
Wegman 1996, Pugliese et al 2001). The relative risk ratio of the I/I genotype vs. I/III or 
III/III has been reported to be moderate (in the 3-5 range) and it accounts for about 10% of 
the familial clustering of T1D (Jahromi & Eisenbarth 2006). However, analyses suggest that 
it is not possible to discriminate effects of the VNTR from other polymorphisms in this 
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region (Shaltout et al 2002) and that at least two other polymorphisms (-23HphI and 
+1140A/C) may be important(Heath et al 1998). Moreover, by measuring the HphI 
polymorphism (in tight linkage disequilibrium with the VNTR) (Stead et al 2000), Metcalfe 
and coworkers showed that homozygosity for the predisposing INS genotype increases the 
likelihood that identical twins will be concordant for T1D (Metcalfe et al 2001). 
Insulin associated susceptibility and resistance may derive from quantitative differences in 
INS transcription in the specialized antigen presenting cells found in thymus and peripheral 
lymphoid tissues, where production of self-antigens such as proinsulin may be crucial for 
the shaping and maintaining of a self-tolerant T cell repertoire (Vafiadis et al 1997, Alizadeh 
& Koelman 2008). Such mechanisms may influence the probability of developing 
autoimmune responses to insulin as a key autoantigen in T1D. 
2.2.2B2 LYP gene - PTPN22 
LYP gene (encoded by PTPN22 gene belongs to a family of protein tyrosine phosphatases 
(PTPs) that are involved in modulating T-cell activation. The PTPN22 gene has been 
associated with development of T1D and other autoimmune diseases (Jahromi & Eisenbarth 
2006). Recently, significantly associated of PTPN22 C1858T variant was found to be to lower 
fasting C-peptide levels, poorer glycemic control in recent onset of T1D subjects  and to 
higher GADA in T1D patients with long disease duration (Mortensen et al 2010).  
The gene encodes a lymphoid tyrosine phosphatase (LYP) which by dephosphorylation of 
Src family kinases negatively regulates T cell receptor (TCR) signaling. The current working 
hypothesis suggest that the risk carrying allele, T1858, suppresses TCR signaling more 
efficiently during thymic development resulting in survival of auto reactive T-cells 9( et al 
2011). Bottini  and co-workers evaluated a functional polymorphism in the lyp gene (no 
relation to the lymphopenia gene of the BB rat) in two series of patients with T1D, (Bottini et 
al 2004). They suggested the possible use of PTPN22 SNPs as a prognostic factor for disease 
severity and variability in autoimmune diseases (Bottini et al 2006).  
There are evidence indicating that the diabetes associated allele may result in a “gain of 
function” (Bottini et al 2006) and thereby contribute to T cell activation. The odds ratio was 
approximately 1.7, making this polymorphism the most potent after HLA and INS. The 
polymorphism appears to be a missense mutation that changes an arginine at position 620 to 
a tryptophan and thereby abrogates the ability of the molecule to bind to the signaling 
molecule Csk (Bottini et al 2006, Begovich et al 2004). Consistent with a general effect on 
immune function is the finding that the minor tryptophan encoded allele is associated with 
a series of autoimmune disorders including T1D, and other autoimmune diseases (Begovich 
et al 2004, Kyogoku et al 2004). Multiple recent studies have confirmed the association of 
this missense mutation with T1D including an extensive study from United Kingdom. It is 
possible that polymorphisms in linkage disequilibrium with R620W determine increased 
risk of autoimmunity rather than the polymorphism, but this seems unlikely given the rapid 
confirmation of this polymorphism's association with multiple forms of autoimmune 
disease in multiple populations and its functional significance.  
Recently Nielsen and coworkers have further investigated in the association of PTPN22 
C1858T with the disease progression as assessed by liquid meal associated C-peptide and 
proinsulin, HbA1c, and daily insulin dose, IDAA1C (Petrone et al 2008), production of 
pancreatic islet antibodies and new onset of T1D( Mortensen et al 2009). They have shown 
that PTPN22 gene variant may be associated with changes in residual ǃ-cell function and 
disease pathogenesis during the first year after onset of T1D (Neilsen et al 2011). 
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2.2.2B3 Cytotoxic T Lymphocyte Antigen-4  
CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) is a molecule on T-cells that plays a 
critical role in regulating natural immune responses.CTLA4 has attracted interest for many 
years, and multiple studies have established association or linkage between this chromosomal 
region and autoimmune diseases, particularly T1D(Nistico et al 1996,  Ueda et al 2003, , Anjos 
et al 2004, Concannon et al 2005). Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene is located 
on chromosome 2q33, is one of the confirmed T1D susceptibility loci. This 300-kilobase region 
is known to contain at least three genes: CD28, CTLA-4, and the inducible costmulatory 
molecule (ICOS) gene (Kavvoura & Ioannidid 2005). The LD patterns in this region define two 
blocks, one comprising the CD28 gene and another including CTLA4 and the 5’ end of ICOS. 
The first studies limited the signals to the CTLA4-ICOS block and subsequent research 
determined that the SNPs selected had functional effects on the CTLA- 4 protein while the 
expression and function of ICOS did not suffer any change. The CTLA4 gene has four exons 
and three introns. Exon 1 codes for the leader peptide of the protein, exon 2 delivers the 
ligand-binding domain, exon 3 is the transmembrane  domain and exon 4 the cytoplasmic tail. 
Two of the most studied and replicated polymorphisms in CTLA4 are rs231775 (+A49G), 
located in exon 1, and rs3087243 (+6230G>A, also known as CT60) in the 3' region. The A allele 
of rs231775 codes for a threonine in position  17 of CTLA-4, forming a threonine-X-asparagin 
glycosilation site. The mutant G allele (alanine) causes an aberrant  glycosilation of the derived 
protein and lower levels of  membrane-bound CTLA-4 in in vitro experiments( Ueda et al 
2003).  The change CT60, a transition from a guanine to an adenine in position +6230 of the 
gene, is correlated to higher levels of a soluble isoform of the CTLA-4 protein. 
The CTLA-4 receptor has two variants derived from alternative splicing: the membrane-
bound and the soluble  form that lacks the transmembrane domain. It is believed that the 
soluble isoform contributes to downregulate the  activation of T cells by binding to CD80-
CD86 receptors in  antigen presenting cells and preventing the stimulation of CD28. Ueda 
and coworkers found a correlation between high levels of sCTLA-4 in serum and the 
protective A allele in the CT60 polymorphism(Ueda et al 2003). By mechanisms as yet 
unknown, the protective allele augments the levels of sCTLA-4 mRNA and patients who 
carry this allele have higher levels of free sCTLA-4 in serum, that most likely contribute to 
control the activation of the immune system. 
Kavvoura and Ioannidis have a meta analysis on three of them and concluded that the A 
(49) G gene polymorphism in exon 1 is associated with T1D (Kavvoura & Ioannidis 2005). 
They have also reported a significant ethnic variation in that polymorphism. On the other 
hand, the A (CT60) G gene polymorphism have been studied in parallel with A (49) G in 
different in Caucasian as well as Asian population.  
2.2.2B4 Other non-MHC genes and loci 
Increasing studies have identified different non-MHC genes apart from insulin gene region, 
PTPN22, CTLA-4 to be associated in T1D pathogenesis. Other non-MHC genes might also 
be important in triggering the pathogenesis of T1D. However, further large scale 
confirmatory association studies might be required. The polygenic nature of T1D 
pathogenesis functions as a network of genes and loci that exert its effect in the triggering of 
the disease onset. Our series of human genetic of cytokines work have identified the effect of 
genetic polymorphisms in cytokines in the pathogenesis of T1D, Figure 1. Given the 
mediatory role of cytokines in the immune system they might be of a good therapeutic 
value. However, these findings require large scale confirmatory studies. 
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Fig. 1. Diagrammatic presentation of effects of cytokines gene polymorphisms in T1D. 
This schematic diagram explains the possible effects of cytokines in the initiation triggering 
of T1D by signals from either environmental factors “A” or immunogenic factors “B” or 
both. Release of IL-6 would change the counterbalance between TH1/TH2 “C” cytokines 
level. Increase level of TH1, IFN-Ǆ, cause the cytotoxic process of break down of ǃ-cell by 
CD8. As a result of deviation of cytokine cross regulation to TH1 dominance TH3 
lymphocyte subset produce immunosuppressive cytokines, TGF- ǃ1, however, due to 
genetic malfunction this cytokines are proved not to be able to bring TH1/TH2 back to 
normal position, D. Which will lead to the death of pancreatic ǃ cell. This is a simplified 
schematic descriptions of the impact of cytokines in the pathogenesis of T1D, for detail 
please refer to Jahromi et al 2000, 2000a and 2010. 
3. Conclusion 
An increasing number of studies indicate that genetic factors influence both susceptibility to 
and resistance to T1D. Several chromosomal regions have been linked with the disease, 
suggesting the polygenic nature of disorder in most families. A few rare families have 
dramatic Mendelian mutations leading to immune mediated diabetes.  
Although DR and DQ alleles and their linkage disequilibrium pattern can explain a major 
portion of disease risk there is evidence for additional genes linked or within the MHC 
influencing risk. Combination of genes linked to the MHC, have a major effect on risk of 
T1D in addition to the known potent effects of HLA DR and DQ alleles.  
Further, other non-MHC genes such as INS, PTPN22 and CTLA-4 and others with small but 
significant effects might contribute to pathogenesis of T1D. Differences in disease risk 
between populations are likely due in part to the distribution within populations of DR and 
DQ haplotypes. However, the major genetic factors, probably linked to the MHC remain to 
be defined that will contribute to the remarkable differences in T1D incidence. With the 
β cell death  
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recent biotechnological advancements extensive genetic typing and the formation of 
cooperative global genetic study groups, international HapMap and Genome Wide 
Association (GWA) should enhance the speed at which true gene(s) for T1D will be 
unraveled. 
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